Parliament Workbench
Data: Motions & questions to 26 Nov 2026

Written Question · S7W-02639 · Session 7

What recent assessment it has made of the clinical efficacy and cost-effectiveness of integrating the distribution of rapid testing strips,…

Answered Asked by Paul Sweeney Lab Lodged 21 Aug 2026

The question

To ask the Scottish Government what recent assessment it has made of the clinical efficacy and cost-effectiveness of integrating the distribution of rapid testing strips, including those detecting fentanyl and nitazenes, into existing harm-reduction networks and needle exchanges.

The answer

Answered by Maree Todd on 22 Sep 2026 · 32 days after it was lodged, on time

The Scottish Government is committed to continuing to explore innovative drug harm reduction measures. We have not undertaken a formal national assessment of the clinical efficacy or cost-effectiveness of integrating rapid testing strips into existing harm reduction networks or injecting equipment provision services, however we are aware that nitazene test strips are available from some services in Scotland.We are aware of both the potential benefits and limitations of rapid testing strips as harm reduction tools, including their role in supporting engagement and risk reduction, alongside recognised limitations relating to accuracy and false negative results. We are working with partners including Public Health Scotland and Healthcare Improvement Scotland to consider the evidence and inform appropriate Scottish guidance.

In the Official Report

No contribution in the Official Report cites S7W-02639 by reference.